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A sensitive spectrophotometric method for the determination
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A simple, accurate and sensitive spectrophotometric me-
thod for determination of H2-receptor antagonists: cime-
tidine (CIM), famotidine (FAM), nizatidine (NIZ), and
ranitidine hydrochloride (RAN) has been fully develo-
ped and validated. The method was based on the reac-
tion of these drugs with NBS and subsequent measure-
ment of the excess N-bromosuccinimide by its reaction
with p-aminophenol to give a violet colored product
(lmax at 552 nm). Decrease in the absorption intensity
(DA) of the colored product, due to the presence of the
drug, was correlated with its concentration in the sample
solution. Different variables affecting the reaction were
carefully studied and optimized. Under optimal condi-
tions, linear relationships with good correlation coeffici-
ents (0.9988–0.9998) were found between DA values and
the corresponding concentrations of the drugs in a con-
centration range of 8–30, 6–22, 6–25, and 4–20 mg mL–1
for CIM, FAM, NIZ, and RAN, respectively. Limits of de-
tection were 1.22, 1.01, 1.08, and 0.74 mg mL–1 for CIM,
FAM, NIZ, and RAN, respectively. The method was vali-
dated in terms of accuracy, precision, ruggedness, and
robustness; the results were satisfactory. The proposed
method was successfully applied to the analysis of the
above mentioned drugs in bulk substance and in phar-
maceutical dosage forms; percent recoveries ranged
from 98.5 ± 0.9 to 102.4 ± 0.8% without interference from
the common excipients. The results obtained by the pro-
posed method were comparable with those obtained by
the official methods.
Keywords: H2-receptor antagonists, N-bromosuccinimide,
p-aminophenol, spectrophotometry, pharmaceutical ana-
lysis
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Histamine H2-receptor antagonists (H2-RAs) competitively inhibit the action of his-
tamine on the H2-receptors of parietal cells and thereby reduce the gastric acid secretion
under daytime and nocturnal basal conditions. H2-RAs are used for short-term treatment
of active duodenal ulcer, active and benign gastric ulcer, pathogenic gastrointestinal hy-
persecretory conditions (e.g., Zollinger-Ellison syndrome), and short-term symptomatic
relief of gastroesophageal refluxes (1). H2-RAs include cimetidine (CIM), famotidine
(FAM), nizatidine (NIZ) and ranitidine hydrochloride (RAN); their chemical structures
are given in Fig. 1.
Because of the therapeutic importance of H2-RAs, several methods have been reported
for their determination in bulk, pharmaceutical dosage forms, and/or biological fluids.
These methods include titrimetry (2), electrochemical methods (3), TLC (4), HPLC (5, 6),
capillary electrophoresis (7), immunoassay (8), fluorimetry (9, 10), and spectrophotomet-
ry (11–17).
N-haloimides have been used as effective oxidizing/brominating agents for the
spectrophotometric determination of many pharmaceutical compounds (18, 19). N-bro-
mosuccinimide (NBS), being the most versatile, is the most commonly used haloimide
(20–22). The analysis involving NBS was based on direct measurement of the chromoge-
nic derivative of the drug, or indirectly by measuring the remaining NBS with color-pro-
ducing reagents susceptible to oxidation or bromination with NBS.
It was reported that p-aminophenol (PAP) is easily susceptible to oxidation with
NBS and gives a violet chromogenic product of lmax at 552 nm (23). The use of NBS/
PAP combination has not been investigated in the spectrophotometric determination of
H2-RAs. The present study describes, for the first time, the use of a NBS/PAP combina-
tion in the development of a new simple spectrophotometric method for determination
of H2-RAs. The analytical procedure involved oxidation of H2-RAs with excess NBS and
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Fig. 1. Chemical structures of the investigated H2-receptor antagonists (H2-RAs).
subsequent measurement of the remaining unreacted NBS by its reaction with PAP to
give a violet colored product that was measured at 552 nm. The decrease in the absorp-
tion intensity (DA) at 552 nm, caused by the presence of the drug, was directly propor-
tional to the amount of the drug in the sample solution.
EXPERIMENTAL
Apparatus
UV-1601 PC (Shimadzu, Japan) and Lambda-3 B (Perkin-Elmer, USA) ultraviolet-
-visible spectrophotometers with matched 1-cm quartz cells were used for all measure-
ments.
Materials and reagent solutions
Cimetidine and famotidine (Sigma Chemical Co., USA), nizatidine (Eli Lilly Co, USA),
and ranitidine hydrochloride (Glaxo-Wellcome, UK) were obtained and used as recei-
ved. Stock standard solutions (0.2 mg mL–1) were prepared. Working standard solutions
were obtained by further dilution of the stock solution with water. N-bromosuccinimde
(Merck, USA) was 0.15% (m/V) aqueous solution prepared fresh daily. p-Aminophenol
(Laba Chemie PVT Ltd., India) was 0.2% (m/V) prepared fresh daily by dissolving PAP
in 1.5% (V/V) hydrochloric acid. All solvents, acids, and other chemicals used through-
out the study were of analytical grade. Doubly distilled water was obtained through a
Nanopure II water purification system (Barnstead/Thermolyne, USA) and was used
throughout the work.
Pharmaceutical formulations
Famotin® tablets (Memphis, Egypt), Antodine® tablets (Amoun Pharmaceutical In-
dustries, Egypt), Servipep® tablets (Novartis Pharma, Egypt), Peptic tablets (Julphar,
UAE), Famotak® tablets (South Egypt Industries Company, Egypt), Gastrodomina® tab-
lets (Medical Union Pharmaceuticals, Egypt), and Antodine® ampoules (Amoun Phar-
maceutical Industries, Egypt) are labeled to contain 40 mg of FAM per tablet or ampoule.
Nizatin® capsules (Hi Pharm, Egypt) are labeled to contain 300 mg of NIZ per capsule.
Ranitidol® tablets (El-Nasr Pharmaceutical Chemicals, Egypt) are labeled to contain 150
mg of RAN per tablet. Ranitak® tablets (South Egypt Industries Company, Egypt) are la-
beled to contain 300 mg of RAN per tablet. Zantac® tablets (Glaxo-Wellcome Egypt,
Egypt), and Ranitidine® tablets (Medical Union Pharmaceuticals, Egypt), Aciloc® tablets
(Sigma, Egypt) are labeled to contain 300 mg of RAN per tablet. Zantac® ampoule (Gla-
xo-Wellcome Egypt) and Ranitidine® ampoule (Medical Union Pharmaceuticals) are la-
beled to contain 50 mg of RAN per ampoule. Cimetidine tablets were simulated in the
laboratory according to the reported formulation and were labeled to contain 300 mg of
CIM per tablet.
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General recommended procedure
One milliliter of the standard or sample solution containing 40–350 mg mL–1 of the
active material was transferred into a 10-mL calibrated flask. One milliliter of NBS solu-
tion (0.15%, m/V) was added, and the reaction was allowed to proceed at room tempera-
ture (25 ± 5 °C) for 15 min. One milliliter of HCl acid (1.5%, V/V) and 1 mL of PAP (0.2%,
m/V) were added. The contents of the flask were mixed and allowed to stand at room
temperature (25 ± 5 °C) for 5 min. The reaction mixtures were made up to volume with
water and absorbances were measured at 552 nm against blank solutions prepared in the
same manner without the drug. For direct measuring of the decrease in the absorbance
intensity (DA values), the positions of the cuvettes for the blank and sample were ex-
changed. Calibration graphs were constructed by plotting the DA values vs. the corres-
ponding drug concentration, and the amount of the drug in each particular sample was
calculated from its corresponding calibration curve.
Determination of accuracy by the standard addition method
The accuracy of the proposed method was evaluated by addition of varying amounts
of the authentic materials. Three concentrations were added for each analyte; 5.0, 15.0
and 25.0 mg were added for CIM and NIZ, whereas 2.5, 7.5 and 17.5 mg were added for
FAM and RAN to a dosage form containing a fixed amount of the active ingredient, and
the recovery percentage was determined for the added amount. Cimetidine, Servipep,
and Zantac tablets as well as Nizatin capsules were used for the standard addition met-
hod.
Interferences study
Samples were prepared by mixing a known amount (300 mg) of CIM with common
excipients: lactose, sucrose, starch, magnesium stearate, and ascorbic acid (added as sta-
bilizer in the formulation of the ampoule). The mass ratios were 3, 12, 6, 60, and 15 for
lactose, sucrose, starch, magnesium stearate, and ascorbic acid, respectively. The analy-
sis of these laboratory-prepared samples was carried out using the general recommen-
ded procedure, and the recovery values were determined.
Analysis of dosage forms
Tablets and capsules. – Twenty tablets or the contents of 20 capsules were weighed
and finely powdered. An accurately weighed quantity of the powdered tablet or capsule
contents equivalent to 200 mg of the active ingredient was transferred into a 100-mL ca-
librated flask and dissolved in about 50 mL of water. The contents of the flask were swir-
led, sonicated for 5 min, and then made up to the volume with water. The mixtures were
mixed well, filtered and the first portion of the filtrate was rejected. Prepared solution
was diluted 100 times and the resulting solution was used for analysis by the recom-
mended procedure.
Ampoules. – The contents of five ampoules were quantitatively transferred into a
250-mL calibrated flask, made up to the mark with water, and the resulting solution was
used for analysis by the recommended procedure.
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Determination of molar ratio of the reactants by the mole ratio method
H2-RAs with NBS. – One-milliliter aliquots of the drug solution (6.6 ´ 10–3 mol L–1)
were transferred into 25-mL calibrated flasks. To each flask, 1–10-mL aliquots of NBS so-
lution (6.6 ´ 10–3 mol L–1) were added, and the reactions were allowed to proceed for 15
min at room temperature (25 ± 5 °C). One milliliter of hydrochloric acid (1.5%, V/V) and
1 mL of PAP solution (0.2%, m/V) were added to each flask. The reaction mixtures were
allowed to stand at room temperature for 5 min and were made up to volume with wa-
ter. The DA values were measured as described under the general recommended proce-
dure.
NBS with PAP. – One-milliliter aliquots of NBS solution (6.6 ´ 10–3 mol L–1) were
transferred into 25-mL calibrated flasks. To each flask, 1 mL of hydrochloric acid (1.5%,
V/V), and 1–10-mL aliquots of PAP solution (6.6 ´ 10–3 mol L–1) were added. The reac-
tions were allowed to proceed for 5 min at room temperature (25 ± 5 °C) and were then
made up to volume with water. The absorbance was measured at 552 nm against reagent
blanks prepared without NBS.
RESULTS AND DISCUSSION
Optimum conditions
The proposed procedures using NBS and PAP involved two steps; the first involved
treatment of the investigated H2-RAs with a known excess amount of NBS, the second
step involved determination of the remaining unreacted NBS via its reaction with PAP
reagent. The decrease in the absorption intensity (DA) at 552 nm, caused by the presence
of the drug, was directly proportional to the amount of the drug in its sample solution.
Fig. 2 illustrates the absorption spectra of the reaction product of NBS with PAP in the
presence and in the absence of cimetidine, as a representative example of H2-RAs. Simi-
lar patterns were obtained with other H2-RAs.
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Fig. 2. Absorption spectra of: 1) cimetidi-
ne (20 mg mL–1), 2) reaction product of
NBS (0.15%, m/V) and PAP (0.2%, m/V) in
the absence of cimetidine, and 3) the re-
action from 2) in the presence of cimetidi-
ne (20 mg mL–1).
The optimum NBS concentration was found to be 0.15% (m/V). The reaction be-
tween H2-RAs and NBS was found to proceed in neutral medium. However, for comple-
te reaction between NBS and PAP, acidic medium was necessary. The highest DA values
were obtained when hydrochloric acid was used; the optimum concentration of hydroc-
hloric acid at which the maximum readings were obtained was 1.5–2% (V/V). The results
revealed that the reaction was completed within 10–20 min at room temperature (25 ± 5
°C). For more precise reading, the measurements were carried out after 15 min.
Different solvents were tested in order to select the most appropriate solvent for di-
lution. Although the highest readings were obtained when methanol was used, water
was preferred for economic reasons and safe-environment considerations. After dilution
with water, the DA values were found to be stable for at least 60 min.
Stoichiometry and the mechanism
The study of the stoichiometry for the reaction between the investigated H2-RAs
and NBS revealed that the drug/NBS ratio was 1:4 in all cases (i.e., 1 mole of the drug re-
acted with 4 moles of NBS). The molar ratio for the reaction between NBS and PAP was
found to be 4:1. Based on these findings, the reactions of ranitidine with NBS and NBS
with PAP were assumed to proceed according to the pathway given in Scheme I.
Validation of the method
Linearity, limits of detection and quantitation. – In all cases, Beer’s law plots (n = 5) we-
re linear with good correlation coefficients (0.9988–0.9998) in the general concentration
ranges of 8–30, 6–22, 6–25, and 4–20 mg mL–1 for CIM, FAM, NIZ, and RAN, respectively
(Table I). Amin et al. (12, 13) reported the range of 0.1–2.6 mg mL–1. The limits of detec-
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tion (LOD) and limits of quantitation (LOQ) were determined (24) using the formula:
LOD or LOQ = kSDa/b, where k = 3.3 for LOD and 10 for LOQ, SDa is the standard devi-
ation of the intercept, and b is the slope. The LOD and LOQ values ranged from 0.74–
1.22 and 2.25–3.69 mg mL–1, respectively (Table I).
Precision. – The precision (repeatability) of the method was determined by replicate
analysis of five separate solutions of the working standards at three concentration levels
of each drug. Relative standard deviations were 0.8, 0.9, 0.9, and 1.2 for CIM, FAM, NIZ,
and RAN, respectively (Table I) indicating good precision of the proposed methods.
Interferences. – The results of the interferences study showed that no interference
was found from lactose, sucrose, starch, talc, gum acacia, glucose, and magnesium stea-
rate; the recovery of CIM was 99.3–100.7%. This indicated the absence of interferences
from these excipients. On the other hand, ascorbic acid was found to interfere with the
assay procedure. This interference could be eliminated by adding 1 mL of 0.1% (m/V)
aqueous solution of potassium bromate to the ampoule samples prior to their analysis.
Potassium bromate, being a mild oxidant, was used in this experiment to oxidize the as-
corbic acid; however, it was unable to oxidize the drug (RAN). This gave an important
advantage to the proposed method over the method reported by Amin et al. (12, 13) who
did not investigate that interference.
Robustness and ruggedness. – Robustness was examined by evaluating the influence
of a small variation of the method variables including the concentration of analytical re-
agents and reaction time on the performance of the proposed methods. In these experi-
ments, one parameter was changed whereas the others were kept unchanged, and the
recovery percentage was calculated each time. It was found that small variations in
these variables did not affect the method significantly. This was an indication of the reli-
ability of the proposed method during its routine application for analysis of the investi-
gated drugs. Ruggedness was tested by applying the proposed methods to the assay of
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Table I. Analytical parameters for the analysis of H2-RAs drugs by the proposed
spectrophotometric method
Parameter CIM FAM NIZ RAN
Linear range (mg mL–1) 8–30 6–22 6–25 4–20
Intercept 0.0043 0.0080 0.0390 0.0026
Slope 0.0222 0.0355 0.0295 0.0400
Correlation coefficient 0.9989 0.9998 0.9995 0.9988
e ´ 103 (L mol–1 cm–1) 6.710 11.960 10.060 16.100
LOD (mg mL–1) 1.22 1.01 1.08 0.74
LOQ (mg mL–1) 3.69 3.06 3.28 2.25
Ruggedness (RSD, %) 0.84 0.73 1.06 0.85
Repeatability (RSD, %) 0.81 0.88 0.92 1.22
Recovery (%)a 99.8–100.2 99.9–101.2 99.7–100.5 98.8–99.6
a Values are the mean of three determinations.
the investigated drugs using the same operational conditions but using two different in-
struments in two different laboratories and different elapsed time. Results obtained from
lab-to-lab and day-to-day variations were found to be reproducible, the full range of re-
covery values was 98.4–101.3% and the RSD was 0.8, 0.7, 1.1, and 0.9% for CIM, FAM,
NIZ and RAN, respectively (Table I).
Accuracy and application of the proposed method to analysis of dosage forms
The accuracy of the proposed method was evaluated by recovery studies using the
standard addition method. The obtained recovery values were 99.8–100.2, 99.9–101.2,
99.7–100.5, and 98.8–99.6% for CIM, FAM, NIZ, and RAN, respectively (Table I). This in-
dicated high accuracy of the proposed method.
It is evident from the aforementioned results that the proposed method gave satis-
factory results with the investigated drugs in bulk. Their pharmaceutical dosage forms
were subjected to the analysis of the active ingredient by the proposed method and the
official titrimetric method stated in the British Pharmacopoeia (25). The label claim, as
percentage, ranged from 98.5–102.4% (Table II). These results were compared with those
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Proposed method Official methodc
Cimetidine® tablets 100.3 ± 0.9 98.9 ± 0.6 2.20 2.43
Famotine® tablets 101.3 ± 0.9 99.3 ± 0.7 2.06 1.66
Servipep® tablets 102.1 ± 1.7 100.6 ± 1.2 2.05 1.71
Peptic® tablets 98.5 ± 1.0 97.2 ± 1.5 2.34 1.44
Famotak® tablets 100.9 ± 1.0 99.4 ± 0.7 2.22 2.03
Antodine® tablets 99.5 ± 0.8 98.6 ± 0.7 1.08 1.29
Gastrodomina® tablets 100.5 ± 1.1 99.2 ± 0.7 2.41 1.95
Antodine® ampoules 102.4 ± 0.8 101.5 ± 0.6 1.87 1.63
Nizatin® capsules 99.6 ± 1.8 98.1 ± 1.3 2.19 1.72
Ranitidine® tablets 99.9 ± 0.8 98.4 ± 0.7 2.41 0.66
Zantac® tablets 98.8 ± 1.3 97.3 ± 0.8 2.70 1.95
Ranitak® tablets 99.7 ± 1.1 97.6 ± 0.7 2.23 2.13
Ranitidol® tablets 98.5 ± 1.1 97.2 ± 1.5 1.73 1.63
Aciloc® tablets 99.6 ± 1.1 98.7 ± 0.8 1.83 1.38
Zantac® ampoules 101.8 ± 1.6 100.1 ± 1.3 1.71 1.92
Ranitidine® ampoules 99.8 ± 0.8 98.6 ± 0.7 1.18 1.70
a Values are mean ± SD, n = 5.
b Theoretical values for t and F at 95% confidence limit and n = 5 were 2.78 and 6.39, respectively.
c Reference 25.
obtained from the official method by statistical analysis. No significant differences were
found between the calculated and theoretical values of t- and F-tests at 95% confidence
level proving comparable accuracy and precision in the analysis of the investigated dru-
gs in their dosage forms.
CONCLUSIONS
The results demonstrated the usefulness of the NBS-PAP system in the spectropho-
tometric determination of H2-receptor antagonists. The proposed method was advanta-
geous over the previously reported spectrophotometric methods in terms of simplicity,
selectivity and applicability to analysis of four H2-RAs.
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S A @ E T A K
Osjetljiva spektrofotometrijska metoda za odre|ivanje antagonista H2-receptora
uz uporabu N-bromsukcinimida i p-aminofenola
IBRAHIM A. DARWISH, SAMIHA A. HUSSEIN, ASHRAF M. MAHMOUD i AHMED I. HASSAN
Razvijena je i validirana ispravna, jednostavna i osjetljiva spektrofotometrijska me-
toda za odre|ivanje antagonista H2-receptora: cimetidina (CIM), famotidina (FAM), ni-
zatidina (NIZ) i ranitidin hidroklorida (RAN). Metoda se temelji na reakciji tih ljekovitih
tvari s N-bromsukcinimidom (NBS). Vi{ak N-bromsukcinimida odre|uje se nakon reak-
cije s p-aminofenolom s kojim daje ljubi~asti produkt (lmax pri 552 nm). Smanjenje
apsorpcijskog intenziteta (DA) obojenog produkta, zbog prisutnosti ljekovite tvari kore-
lirano je s njegovom koncentracijom u otopini uzorka. Prou~avane su razli~ite varijable
koje utje~u na reakciju. Linearno koncentracijsko podru~je za CIM, FAM, NIZ i RAN, s
koeficijentom korelacije od 0,9988 do 0,9998, iznosi 8–30, 6–22, 6–25 odnosno 4–20 mg
mL–1. Granice detekcije bile su 1,23, 1,02, 1,09 i 0,75 g mL–1 za CIM, FAM, NIZ, odnosno
RAN. Predlo`ena metoda je uspje{no primijenjena za analizu navedenih ljekovitih tvari
i ljekovitih pripravaka. Nepreciznost od 0,7 do 1,2% i visoka ispravnost (analiti~ki pov-
rat izme|u 98,5 i 102,4%), bez interferencije uobi~ajenih pomo}nih tvari, ukazuju na do-
bru analiti~ku metodu. Rezultati dobiveni predlo`enom metodom usporedivi su s rezul-
tatima dobivenim slu`benom metodom.
Klju~ne rije~i: antagonisti H2-receptora, N-bromsukcinimid, p-aminofenol, spektrofotometrija, far-
maceutska analiza
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